Contributors: Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR); Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA); Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office Genève, Suisse (OMS / WHO); Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM); European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA); Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin (HU Berlin); McMaster University Hamilton, Ontario; National Institute of Allergy and Infectious Diseases Bethesda (NIAID-NIH); National Institutes of Health Bethesda, MD, USA (NIH); Upper Airways Research Laboratory; Universiteit Gent = Ghent University = Université de Gand (UGENT); National Institute for Health and Welfare Helsinki; University Hospitals Leuven Leuven; VU University Medical Center Amsterdam; Center for Rhinology and Allergology = Zentrum für Rhinologie und Allergologie; Philipps Universität Marburg = Philipps University of Marburg; Nova Southeastern University (NSU); Hospital Quirónsalud Bizkaia Bilbao; Transilvania University of Brasov; Charité - UniversitätsMedizin = Berlin University Medicine; iQ4U consultants Ltd; CHU Dijon; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); Woolcock Institute of Medical Research Sydney; The University of Sydney; Allergist La Rochelle; Laval University Medical center; Université Laval Québec (ULaval); Quebec Heart and Lung Institute; Ghent University Hospital; National Heart and Lung Institute London (NHLI); Imperial College London-Royal Brompton and Harefield NHS Foundation Trust; Humanitas University Milan (Hunimed); Institute for Immunological Research (University of Cartagena); Vall d'Hebron University Hospital Barcelona; RETIC ARADyAL; University of South Florida Tampa (USF); SOS Allergology and Clinical Immunology; Unidade de Ciencias Biomoleculares Aplicadas (UCIBIO); Requimte; Universidade do Porto = University of Porto-Departamento de Química (DQ); Faculdade de Ciências e Tecnologia = School of Science & Technology (FCT NOVA); Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Faculdade de Ciências e Tecnologia = School of Science & Technology (FCT NOVA); Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto = University of Porto-Departamento de Química (DQ); Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA); ProAR – Nucleo de Excelencia em Asma; Universidade Federal da Bahia = Federal University of Bahia (UFBA); Medical Consulting Czarlewski; "Federico II" University of Naples Medical School; Laboratoire de Pharmacologie Respiratoire UPRES EA220; UPRES EA 220; Pôle des maladies respiratoires; Hôpital Foch; Washington University School of Medicine Saint Louis, MO; Sagamihara National Hospital Kanagawa, Japan; CHU Estaing Clermont-Ferrand; CHU Clermont-Ferrand; Department of Otorhinolaryngology Amsterdam; Academic Medical Centre Amsterdam; University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA)-University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA); Center of Research in Health Technologies and Information Systems (CINTESIS); Universidade do Porto = University of Porto; Allergist Reims; Cerrahpasa Faculty of Medicine, Istanbul University; Erasmus University Medical Center Rotterdam (Erasmus MC); Skin and allergy hospital Helsinki, Finland; Odense University Hospital Odense, Denmark; University General Hospital of Heraklion; Chiba University Hospital; Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel); Wrocław Medical University; Ukrainina Medical Stomatological Academy Poltava, Ukraine; Federal Medicobiological Agency Moscow, Russian Federation; Hacettepe University School of Medicine; DRK Kliniken Berlin, Westend; Medical University of Łódź (MUL); Barlicki University Hospital; Vilnius University Vilnius; Institute of Biomedicine and Molecular Immunology (IBIM); Hospital Medica Sur Mexico City, Mexico; KYomed INNOV Montpellier; Ho Chi Minh City University of Medicine; The University of Tennessee Health Science Center Memphis (UTHSC); Oslo University Hospital Oslo; University of Beira Interior Portugal (UBI); Centro Hospitalar de Lisboa Central E.P.E; NOVA Medical School - Faculdade de Ciências Médicas (NMS); Universidade Nova de Lisboa = NOVA University Lisbon (NOVA); Sachs’ Children and Youth Hospital Stockholm, Sweden; Karolinska Institutet Stockholm; Center for Allergy and Immunology and Respiratory Diseases; Département d'Information Médicale CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); University Hospital of Cologne Cologne; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Universitat de Barcelona (UB); Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES)
نبذة مختصرة : International audience ; The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.
Processing Request
No Comments.